Skip to main content

Table 1 Melanoma cell line sensitivity to PI3K/Akt and mTOR pathway inhibition

From: Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

Compound

Target

IC50±SEM

B16.F10

A375

RPMI

SH4

MeWo

MEL-JUSO

MK-2206

Pan-AKT

0.29±0.05

4.76±0.58

1.92±0.36

3.11±0.91

1.26±0.01

3.03±0.35

ZSTK474

PI3K

0.95±0.33

2.69±1.14

0.51±0.05

2.80±0.81

1.06±0.07

3.47±0.28

KU-0063794

Pan-mTOR

0.68±0.26

1.90±1.45

1.63±0.28

1.71±0.86

0.97±0.05

1.84±0.12

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us